LARIMAR THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- LARIMAR THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 0.00 shares.
- LARIMAR THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 4.00K shares.
- LARIMAR THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2024-12-31 was 8.44K shares, a 166.49% increase year-over-year.
- LARIMAR THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2024-09-30 was 4.11K shares.
- LARIMAR THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 15.40K shares, a 34.35% increase from fiscal 2023.
- LARIMAR THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 11.47K shares.
- LARIMAR THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2016 was 35.00K shares, a 91.48% decline from fiscal 2015.
- LARIMAR THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2015 was 410.70K shares, a 103091.21% increase from fiscal 2014.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | |
| 2026-03-31 | 4.00K shares 10-Q · filed 2026-05-14 | |
| 2024-12-31 | 8.44K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | 15.40K shares 10-K · filed 2025-03-24 |
| 2024-09-30 | 4.11K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30 | 10.13K shares derived: sum of 4 quarters · filed 2024-10-30 |
| 2024-06-30 | 2.50K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | |
| 2024-03-31 | 356.00 shares 10-Q · filed 2024-05-09 | |
| 2023-12-31 | 3.17K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | 11.47K shares 10-K · filed 2024-03-14 |
| 2016-12-31 | 35.00K shares 10-K · filed 2017-03-10 | |
| 2015-12-31 | 410.70K shares 10-K · filed 2016-03-15 | |
| 2014-12-31 | 398.00 shares 10-K · filed 2015-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |